Physician profile
Andrew Win
NPI 1487228128
$1,599.43
in general payments reported to CMS, 2019-2025
21 companies · $729 in 2025
The $729 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $22.41 · 2024: $848 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,599.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $248.39 | 2024 | Austedo Xr |
| Inspire Medical Systems, INC. | $192.07 | 2025 | Inspire |
| Gilead Sciences, INC. | $146.63 | 2024 | Vemlidy |
| Abbvie INC. | $137.14 | 2025 | |
| Noven Pharmaceuticals, INC. | $124.98 | 2024 | Xelstrym |
| Janssen Pharmaceuticals, INC | $124.95 | 2024 | Invega Sustenna |
| Exact Sciences Corporation | $99.16 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.07 | 2024-2025 | Xifaxan |
| Amgen INC. | $76.30 | 2024-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $72.03 | 2024-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $47.98 | 2024-2025 | Airsupra |
| Dexcom, INC. | $44.57 | 2025 | Dexcom G6 Transmitter |
| Eisai INC. | $40.70 | 2024-2025 | |
| Corcept Therapeutics | $34.27 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $22.41 | 2023 | Lynparza, Keytruda |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.53 | 2025 | Jardiance |
| Antares Pharma, INC. | $19.24 | 2025 | Xyosted |
| Pfizer INC. | $18.61 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.08 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $15.95 | 2024 | Trelegy Ellipta, Arexvy |
| Irhythm Technologies, INC. | $14.37 | 2024 | Zio Xt Patch, Zio Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Win listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.